



King's Research Portal

DOI:

[10.1016/j.jacc.2017.10.093](https://doi.org/10.1016/j.jacc.2017.10.093)

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

O'Gallagher, K., Khan, F., Omar, S. A., Kalra, S., Danson, E., Cabaco, A. R., Martin, K., Melikian, N., Shah, A. M., & Webb, A. J. (2018). Inorganic Nitrite Selectively Dilates Epicardial Coronary Arteries. *Journal of the American College of Cardiology*, 71(3), 363-364. <https://doi.org/10.1016/j.jacc.2017.10.093>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Letters

Inorganic Nitrite Selectively Dilates Epicardial Coronary Arteries



Inorganic nitrite (NO_2^-) as sodium nitrite or derived from dietary nitrate found in green leafy vegetables and beetroot has potential as a tolerance-free therapy in heart failure with preserved ejection fraction (1),


including pulmonary hypertension-associated heart failure with preserved ejection fraction (2). Nitrite affects small and large arteries and veins. Previous studies demonstrated hypoxia (vs. normoxia) enhanced nitrite-induced dilation by 30% to 50% in small-resistance arterioles but not veins (because venous blood is already desaturated) (3). We recently demonstrated that nitrite selectively dilates peripheral conduit arteries in a normoxia-dependent/hypoxia-inhibited manner and selectively lowers aortic blood pressure (afterload) (4). We confirmed this latter effect with 6 months' dietary nitrate (beetroot juice) in 126 patients (5). We also found that nitrite has selectivity similar to that of nitroglycerin (a.k.a., glyceryl trinitrate [GTN]) for conduit arteries versus small-resistance arterioles (4). We therefore investigated whether nitrite also selectively vasodilated epicardial coronary (conduit) arteries.

Following institutional and ethical approvals and informed consent, we recruited patients undergoing diagnostic coronary angiography, including those with an angiographically normal coronary artery and without previous coronary intervention.

A 0.014-inch coronary Doppler wire (Flow Wire, Phillips Volcano, Amsterdam, the Netherlands) was positioned within the proximal artery, and average peak velocity (APV) was measured following 5-min infusions of 0.9% saline (baseline), low-dose sodium nitrite (2.6 $\mu\text{mol}/\text{min}$), high-dose sodium nitrite (26 $\mu\text{mol}/\text{min}$), and GTN (1 $\mu\text{g}/\text{min}$). Angiographic images were obtained simultaneously. Quantitative coronary analysis was performed offline with measurements of vessel diameter (d) in the 5-mm segment distal to the tip of the Doppler wire. Coronary blood flow (CBF) (cm^3/s) was calculated according to the equation: $\text{CBF} = (\text{APV}/2) \times \text{cross-sectional area}$. Coronary resistance ($\text{mm Hg}/\text{cm}^3/\text{s}$) was calculated as mean arterial pressure divided by CBF.

Nine patients (mean 56 years of age; 5 males; 78% hypertensive) received doses of both nitrite and GTN and had angiographic and Doppler flow traces of sufficient quality to be included in the analysis. The higher dose of nitrite (26 $\mu\text{mol}/\text{min}$) and GTN significantly dilated the coronary artery compared to baseline, where mean diameter change was: +8.9% (95% confidence interval [CI]: +2.0 to +15.8) ($p = 0.01$)

FIGURE 1 Percentage of Changes



(A) Coronary Artery Diameter. **(B)** Coronary resistance. **Nitrite (2.6)** and **Nitrite (26)** denote nitrite (2.6 $\mu\text{mol}/\text{min}$) and nitrite (26 $\mu\text{mol}/\text{min}$), respectively. Data are mean \pm SEM. * $p < 0.05$ vs. baseline; † $p < 0.05$ vs. nitrite (2.6 $\mu\text{mol}/\text{min}$); ‡ $p < 0.05$ vs. nitrite (26 $\mu\text{mol}/\text{min}$). GTN = glyceryl trinitrate.

and +10.8% (95% CI: +1.0 to +20.5) ($p = 0.03$); respectively (Figure 1A), with no significant differences between nitrite and GTN ($p = 0.45$). The lower dose of nitrite (2.6 $\mu\text{mol}/\text{min}$) had no significant effect (+3.9%; 95% CI: -2.8 to +10.6; $p = 0.30$).

GTN increased coronary flow relative to that of baseline (median [interquartile range (IQR)]: +23.9% (IQR: +6.3 to +72.7); $p = 0.02$). Nitrite (2.6 $\mu\text{mol}/\text{min}$ and 26 $\mu\text{mol}/\text{min}$) lacked significant effect on coronary flow: +12.0% (IQR: -10.2 to +24.1); $p > 0.99$; and +16.9% (IQR: +3.2 to +64.4); $p > 0.99$, respectively. This occurred despite relatively high estimated intracoronary nitrite concentrations of 73.7 μM (IQR: 57.8 to 154.9 μM) for nitrite (2.6 $\mu\text{mol}/\text{min}$) and 705 μM (IQR: 555 to 1,179 μM) for nitrite (26 $\mu\text{mol}/\text{min}$).

GTN also lowered coronary resistance relative to that of baseline, mean: -29.3% (95% CI: -52.8 to -5.9) ($p = 0.02$), and compared to nitrite (26 $\mu\text{mol}/\text{min}$) mean: -10.4% (95% CI: -18.3 to -2.4) ($p = 0.01$). By contrast, nitrite (2.6 $\mu\text{mol}/\text{min}$ and 26 $\mu\text{mol}/\text{min}$) had no significant effect on coronary resistance, mean: -11.1% (95% CI: -36.7 to +14.5) ($p = 0.52$); and mean: -19.0% (95% CI: -43.4 to +5.4) ($p = 0.13$), respectively (Figure 1B).

There were no significant overall differences in central systolic, diastolic, or mean blood pressure levels with any of the interventions compared to baseline. Heart rate changed -3.1 beats/min (95% CI: -0.2 to -6.1) ($p = 0.02$) with nitrite (2.6 $\mu\text{mol}/\text{min}$) but not with nitrite (26 $\mu\text{mol}/\text{min}$) or GTN.

In summary, these are the first data to show that inorganic nitrite dilates epicardial coronary arteries; moreover, this dilation was selective (and dose-dependent). Although the results should be interpreted with caution, given the small sample size, the indirect measurements of coronary flow, and the trend toward a change in coronary flow/resistance, they support our findings in the peripheral circulation (4) of nitrite's physiological action as a normoxia-dependent selective conduit artery dilator over resistance arteries, even in the metabolically active myocardium. These findings also have important implications for our understanding of the potential beneficial cardiovascular properties of nitrite derived from dietary nitrate sources such as beetroot and green leafy vegetables: nitrite acts principally on large, rather than small vessels in the heart.

Kevin O'Gallagher, MBBS
Faisal Khan, MBBS
Sami A. Omar, MBBS, PhD
Sundeep Kalra, MA, MBBS
Edward Danson, BM, BCh, DPhil
Ana R. Cabaco, MSc

Katherine Martin, MSc
Narbeh Melikian, MD
Ajay M. Shah, MD
*Andrew J. Webb, MBBS, PhD

*King's College London British Heart Foundation Centre
School of Cardiovascular Medicine and Sciences
Department of Clinical Pharmacology
St. Thomas' Hospital
Westminster Bridge Road
London, SE1 7EH
United Kingdom

E-mail: andrew.1.webb@kcl.ac.uk

<https://doi.org/10.1016/j.jacc.2017.10.093>

© 2018 by the American College of Cardiology Foundation. Published by Elsevier.

Please note: The authors' work was supported by the British Heart Foundation and the Department of Health through a National Institute for Health Research (NIHR) Biomedical Research Centre award to Guy's and St. Thomas' National Health Service (NHS) Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. Dr. Webb is a shareholder in HeartBeet, Ltd. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Shah and Webb contributed equally to this work and are joint senior authors.

REFERENCES

- Borlaug BA, Koepp KE, Melenovsky V. Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2015;66:1672-82.
- Simon MA, Vanderpool RR, Nourai M, et al. Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction. *JCI Insight* 2016;1:e89620.
- Maier AR, Milsom AB, Gunaruwan P, et al. Hypoxic modulation of exogenous nitrite-induced vasodilation in humans. *Circulation* 2008;117:670-7.
- Omar SA, Fok H, Tilgner KD, et al. Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures. *Circulation* 2015;131:381-9; discussion, 389.
- Mills CE, Govoni V, Faconti L, et al. Reducing arterial stiffness independently of blood pressure? The randomized, factorial "VaSera" trial in people with or at risk of type 2 diabetes. *J Am Coll Cardiol* 2017;70:1683-4.

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease



Diabetes is associated with a significant decrease in life expectancy (1). In the EMPA-REG OUTCOME trial (NCT01131676), empagliflozin given in addition to standard of care reduced the risk of cardiovascular death by 38% (hazard ratio [HR]: 0.62; 95% confidence interval [CI]: 0.49 to 0.77; $p < 0.0001$) and all-cause mortality by 32% (HR: 0.68; 95% CI: 0.57 to 0.82; $p < 0.0001$) versus placebo in patients with type